scholarly journals Immunoinformatic design of multi epitopes peptide-based universal cancer vaccine using matrix metalloproteinase-9 protein as a target

2020 ◽  
Author(s):  
Abdelrahman H. Abdelmoneim ◽  
Mujahed I. Mustafa ◽  
Miyssa I. Abdelmageed ◽  
Naseem S. Murshed ◽  
Enas A. Dawoud ◽  
...  
Keyword(s):  
Matrix Metalloproteinase ◽  
Cancer Vaccine ◽  
Health Hazard ◽  
Matrix Metalloproteinase 9 ◽  
Reference Sequence ◽  
World Population ◽  
Related Sequence ◽  
Candidate Peptide ◽  
Good Target ◽  
Metalloproteinase 9

AbstractBackgroundCancer remains a major public health hazard despite the extensive research over the years on cancer diagnostic and treatment, this is mainly due to the complex pathophysiology and genetic makeup of cancer. A new approach toward cancer treatment is the use of cancer vaccine, yet the different molecular bases of cancers reduce the effectiveness of this approach. In this work we aim to use matrix metalloproteinase-9 protein (MMP9) which is essential molecule in the survival and metastasis of all type of cancer as a target for universal cancer vaccine design.Methodreference sequence of matrix metalloproteinase-9 protein was obtained from NCBI databases along with the related sequence, which is then checked for conservation using BioEdit, furthermore the B cell and T cell related peptide were analyzed using IEDB website. The best candidate peptide were then visualized using chimera software.ResultThree Peptides found to be good candidate for interactions with B cells (SLPE, RLYT, and PALPR), while ten peptides found as a good target for interactions with MHC1 (YRYGYTRVA, YGYTRVAEM, YLYRYGYTR, WRFDVKAQM, ALWSAVTPL, LLLQKQLSL, LIADKWPAL, KLFGFCPTR, MYPMYRFTE, FLIADKWPA) with world combined coverage of 94.77%. In addition, ten peptides were also found as a good candidates for interactions with MHC2 (KMLLFSGRRLWRFDV, GRGKMLLFSGRRLWR, RGKMLLFSGRRLWRF, GKMLLFSGRRLWRFD, TFTRVYSRDADIVIQ, AVIDDAFARAFALWS, FARAFALWSAVTPLT, MLLFSGRRLWRFDVK, GNQLYLFKDGKYWRF, NQLYLFKDGKYWRFS), with world combined coverage of 90.67%.CONCLUSION23 peptide-based vaccine was designed for use as a universal cancer vaccine which has a high world population coverage for MHC1(94.77%) and MHC2 (90.67%) related alleles.

scholarly journals Immunoinformatics design of multiepitopes peptide-based universal cancer vaccine using matrix metalloproteinase-9 protein as a target

2020 ◽  
pp. 1-18 ◽  
Author(s):  
Abdelrahman H. Abdelmoneim ◽  
Mujahed I. Mustafa ◽  
Miyssa I. Abdelmageed ◽  
Naseem S. Murshed ◽  
Enas dk. Dawoud ◽  
...  
Keyword(s):  
Matrix Metalloproteinase ◽  
Cancer Vaccine ◽  
Matrix Metalloproteinase 9 ◽  
Metalloproteinase 9

473 Adenosine stimulates matrix metalloproteinase-9 secretion by THP-1-derived macrophages

2007 ◽  
Vol 6 (1) ◽  
pp. 102-102
Author(s):  
E VELOT ◽  
I ERNENS ◽  
B HAAS ◽  
C JEANTY ◽  
D ROUY ◽  
...  
Keyword(s):  
Matrix Metalloproteinase ◽  
Matrix Metalloproteinase 9 ◽  
Metalloproteinase 9

Die Bedeutung der Matrix-Metalloproteinase–9 für die Leberhomöostase – Ein induzierbares transgenes Mausmodell

2005 ◽  
Vol 43 (05) ◽  
Author(s):  
F Thieringer ◽  
E Meyer ◽  
P Czochra ◽  
U Schmitt ◽  
JF Garcia-Lazaro ◽  
...  
Keyword(s):  
Matrix Metalloproteinase ◽  
Matrix Metalloproteinase 9 ◽  
Metalloproteinase 9

The role of matrix metalloproteinase 9 and its inhibitors in scarring processes following surgery for primary open-angle glaucoma

2019 ◽  
pp. 72-80
Author(s):  
Е.В. Маркелова ◽  
О.В. Овчинникова ◽  
А.С. Хохлова ◽  
Л.П. Догадова ◽  
А.В. Костюшко ◽  
...  
Keyword(s):  
Matrix Metalloproteinase ◽  
Postoperative Period ◽  
Open Angle Glaucoma ◽  
Matrix Metalloproteinase 9 ◽  
Tissue Inhibitors Of Metalloproteinases ◽  
Open Angle ◽  
Tissue Inhibitors ◽  
Surgery Outcome ◽  
Metalloproteinase 9

Оперативное вмешательство - один из основных методов лечения глаукомы. Однако развитие избыточного рубцевания созданных путей оттока определяет результат хирургического лечения в отдаленные сроки. Процессы рубцевания на данный момент недостаточно изучены. Цель исследования - оценка роли матриксной металлопротеиназы-9, ее ингибиторов в процессах рубцевания у больных с первичной открытоугольной глаукомой после оперативного лечения. Методика. Для выявления возможных маркеров избыточного рубцевания методом твердофазного иммуноферментного анализа определяли содержание матриксных металлопротеиназ-9, тканевых ингибиторов металлопротеиназ 2 и -3 в слезной жидкости у 37 пациентов с активной стадией первичной остроугольной глаукомы в динамике послеоперационного периода. Средний возраст пациентов составил 52,8 лет. В зависимости от исхода оперативного вмешательства все пациенты были разделены на 2 группы - с благоприятным исходом (без избыточного рубцевания) и с неблагоприятным исходом (с избыточным рубцеванием) на месте сформированных дополнительных путей оттока внутриглазной жидкости в послеоперационном периоде. Группа контроля включала 20 человек в возрасте от 50 до 66 лет без сопутствующей офтальмологической и соматической патологии в стадии обострения. Результаты. В динамике показано изменение концентрации матриксной металлопротеиназы-9 и ее ингибиторов в послеоперационном периоде. Анализ данных свидетельствует об обратной зависимости уровня матриксной металлопротеиназы-9 и тканевых ингибиторов металлопротеиназы 2 и 3 типов с исходом операции - чем выше концентрация металлопротеиназы-9 и ниже концентрация тканевых ингибиторов металлопротеиназ 2, -3 в слезной жидкости, тем выше вероятность неблагоприятного исхода в виде рубцевания сформированных дополнительных путей оттока внутриглазной жидкости в послеоперационном периоде. Заключение. Мониторинг уровня металлопротеиназ и их тканевых ингибиторов после проведения хирургического лечения пациентов с первичной открытоугольной глаукомой позволяет прогнозировать раннее рубцевание, дает возможность разработки новых методов лечения как в раннем, так и в позднем послеоперационном периоде. Surgery is one of the major treatments for glaucoma; however excessive scarring of created outflow patways affects the long-term outcome. At the present time, scarring processes are not sufficiently studied. Aim. To evaluate the role of matrix metalloproteinase 9 and its inhibitors in scarring after surgical treatment of open-angle glaucoma. Methods. Concentrations of matrix metalloproteinase 9 and tissue inhibitors of metalloproteinases 2 and 3 were measured in tear fluid of 37 patients (mean age, 52.8) with active primary open-angle glaucoma in dynamics during the postoperative period to identify possible markers of excessive scarring. Based on the surgery outcome, all patients were divided into two groups, with a favorable outcome (without excessive scarring) and an unfavorable outcome (with excessive scarring) in the created additional outflow pathways for the intraocular fluid in the postoperative period. The control group included 20 subjects aged 50-66 without eye disease or somatic disease at exacerbation stage. Results. Analysis of changes in concentrations of matrix metalloproteinase 9 and its inhibitors in the postoperative period showed their inverse relationship with the surgery outcome. The higher was the metalloproteinase 9 level and the lower the level of tissue inhibitors of metalloproteinases 2 and 3 the higher was the probability of unfavorable outcome evident as excessive scarring of the formed additional pathways for tear fluid outflow in the postoperative period. Conclusion. Postoperative monitoring of metalloproteinases and their tissue inhibitors allows to predict early scarring and to develop new treatments both in early and late postoperative periods.

Sign in / Sign up

Export Citation Format

Share Document